AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22180577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy (bupropion, nicotine lozenge, nicotine patch, bupropion + lozenge, patch + lozenge)
Number of subjects: 2846
Study 22180577 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 2846
Study 21226430 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 55
Study 21226430 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 55
Study 17934827 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 198
Study 17934827 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent immunomodulators
Number of subjects: 198
Study 17934827 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 198
Study 15901041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 100 mg tablets (formulation 1)
Number of subjects: 0
Study 15901041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 100 mg tablets (formulation 2)
Number of subjects: 0
Study 12867212 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions
Number of subjects: 0
Study 12867212 — intervention group
Group type: EXPERIMENTAL
Intervention: Less controlled studies
Number of subjects: 0
Study 10338414 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal Tube (ETT)
Number of subjects: 12
Study 10338414 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal‐tracheal Combitube (ETC)
Number of subjects: 12
Study 10338414 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 12
Study 10338414 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices (ETT, LMA, ETC)
Number of subjects: 12
Study 8750405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 20 mg/d)
Number of subjects: 52
Study 8750405 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (2.5 to 10 mg/d)
Number of subjects: 52
Study 2027477 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (100 mg BC‐PS tid)
Number of subjects: 149
Study 2027477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 6487752 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release capsule (15 mg)
Number of subjects: 18
Study 6487752 — intervention group
Group type: COMPARATOR
Intervention: Standard release tablets (5 mg, t.i.d.)
Number of subjects: 18
Study 30690250 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic information group
Number of subjects: 383
Study 30690250 — intervention group
Group type: EXPERIMENTAL
Intervention: Precautionary group
Number of subjects: 383
Study 30690250 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal exposure measurement group
Number of subjects: 383
Study 29037240 — intervention group
Group type: EXPERIMENTAL
Intervention: KH176 single dose of 800 mg
Number of subjects: 0
Study 29037240 — intervention group
Group type: EXPERIMENTAL
Intervention: KH176 multiple doses of 400 mg b.i.d. for 7 days
Number of subjects: 0
Study 29037240 — intervention group
Group type: EXPERIMENTAL
Intervention: KH176 single doses of 2000 mg
Number of subjects: 0
Study 29037240 — intervention group
Group type: COMPARATOR
Intervention: KH176 lower doses
Number of subjects: 0
Study 29037240 — intervention group
Group type: EXPERIMENTAL
Intervention: KH176 pharmacokinetics
Number of subjects: 0
Study 29037240 — intervention group
Group type: EXPERIMENTAL
Intervention: KH176 renal excretion
Number of subjects: 0
Study 29037240 — intervention group
Group type: COMPARATOR
Intervention: KH176 effects on redox biomarkers
Number of subjects: 0
Study 29037240 — intervention group
Group type: EXPERIMENTAL
Intervention: KH176 exposure-response modelling
Number of subjects: 0
Study 25835119 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative one week enteral nutrition (EN)
Number of subjects: 106
Study 25835119 — intervention group
Group type: COMPARATOR
Intervention: Early postoperative enteral nutrition (EN)
Number of subjects: 106
Study 24302596 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum (20 µg)
Number of subjects: 218
Study 24302596 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-alum (2 doses)
Number of subjects: 218
Study 24302596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 22357746 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WW)
Number of subjects: 79
Study 22357746 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat (RW)
Number of subjects: 79
Study 19955927 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative clinical judgment of residual disease after primary cytoreductive surgery
Number of subjects: 20
Study 19955927 — intervention group
Group type: COMPARATOR
Intervention: Prediction models
Number of subjects: 20
Study 17538634 — intervention group
Group type: EXPERIMENTAL
Intervention: NRP with team training
Number of subjects: 100
Study 17538634 — intervention group
Group type: COMPARATOR
Intervention: Standard NRP
Number of subjects: 100
Study 15166533 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-frame intervention (negative consequences of unsafe sex)
Number of subjects: 585
Study 15166533 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-frame intervention (positive consequences of safer‐sex)
Number of subjects: 585
Study 15166533 — intervention group
Group type: COMPARATOR
Intervention: Attention-control clinics (medication adherence)
Number of subjects: 585
Study 11157525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal diamorphine spray
Number of subjects: 404
Study 9551683 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture
Number of subjects: 9
Study 7914754 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1.0 mg/kg bolus followed by 100 micrograms/kg/min continuous infusion)
Number of subjects: 40
Study 7914754 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (equal volume to esmolol)
Number of subjects: 40
Study 7914754 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol and Saline placebo (both groups)
Number of subjects: 40
Study 2972542 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (intracoronary streptokinase)
Number of subjects: 236
Study 2972542 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 236
Study 29996849 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 509
Study 29996849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 509
Study 28098951 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based feedback on hazardous drug exposures plus tailored messages to address barriers
Number of subjects: 393
Study 28098951 — intervention group
Group type: COMPARATOR
Intervention: Web‐based continuing education video
Number of subjects: 393
Study 26143313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 20 mg
Number of subjects: 300
Study 26143313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized morphine 10 mg
Number of subjects: 300
Study 26143313 — intervention group
Group type: COMPARATOR
Intervention: IV morphine 2 mg
Number of subjects: 300
Study 23933155 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC2 gene variants (rs10489202 and rs203861)
Number of subjects: 2115
Study 21205122 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily for 24 weeks
Number of subjects: 503
Study 18457785 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention (Present and Prevent PowerPoint program, 2 sessions of 30 minutes each)
Number of subjects: 880
Study 15867849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 40 microg
Number of subjects: 24
Study 15867849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg
Number of subjects: 24
Study 15867849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg
Number of subjects: 24
Study 15867849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15867849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide (all doses)
Number of subjects: 24
Study 12569144 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (8 Gy)
Number of subjects: 1157
Study 12569144 — intervention group
Group type: COMPARATOR
Intervention: Multiple-fraction radiotherapy (six fractions of 4 Gy each)
Number of subjects: 1157
Study 10376116 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V (250 mg orally twice daily for 4 months)
Number of subjects: 37
Study 10376116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 months)
Number of subjects: 37
Study 8829493 — intervention group
Group type: COMPARATOR
Intervention: Colchicine alone (group I)
Number of subjects: 154
Study 8829493 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine + benzathine penicillin (group II)
Number of subjects: 154
Study 8829493 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group I and group II
Number of subjects: 154
Study 1948722 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective single doses of antianginal drugs
Number of subjects: 62
Study 1948722 — intervention group
Group type: COMPARATOR
Intervention: Ineffective doses of nitrates, calcium antagonists and placebo
Number of subjects: 62
Study 1948722 — intervention group
Group type: COMPARATOR
Intervention: Ineffective single doses of propranolol
Number of subjects: 62
Study 1948722 — intervention group
Group type: COMPARATOR
Intervention: Ineffective single doses of nitrates, calcium antagonists and placebo
Number of subjects: 62
Study 6520009 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received a booklet about exercise)
Number of subjects: 0
Study 6520009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exposure to the booklet)
Number of subjects: 0
Study 30940010 — intervention group
Group type: EXPERIMENTAL
Intervention: Later inquiries
Number of subjects: 10
Study 30940010 — intervention group
Group type: COMPARATOR
Intervention: Earlier inquiries
Number of subjects: 10
Study 29549067 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT) for 14 weeks
Number of subjects: 117
Study 26865254 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-sharing model of locally delivered mental health care integrated into primary health care (PHC) delivered over 18 months
Number of subjects: 324
Study 26865254 — intervention group
Group type: COMPARATOR
Intervention: Established and effective model of specialist mental health care delivered by psychiatric nurses at an out-patient clinic within a centrally located general hospital (active control)
Number of subjects: 324
Study 23503991 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation at low pressure (40-50 mmHg) alternating with fluid medium
Number of subjects: 94
Study 23503991 — intervention group
Group type: COMPARATOR
Intervention: Fluid medium for joint distension at pump pressure (50-70 mmHg)
Number of subjects: 94
Study 23503991 — intervention group
Group type: COMPARATOR
Intervention: Fluid medium for joint distension
Number of subjects: 94
Study 23503991 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 94
Study 22735306 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5‐minute inflation and 5‐minute deflation of a blood pressure cuff)
Number of subjects: 100
Study 22735306 — intervention group
Group type: COMPARATOR
Intervention: Standard care without ischemic preconditioning
Number of subjects: 100
Study 20847403 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 6 months
Number of subjects: 28
Study 20847403 — intervention group
Group type: COMPARATOR
Intervention: Stretching (control) for 6 months
Number of subjects: 28
Study 17710005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg b.i.d.
Number of subjects: 94
Study 17710005 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg b.i.d.
Number of subjects: 94
Study 17710005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 12549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 18
Study 12549941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 18
Study 12549941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10715292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention - researcher helped create an agenda, facilitated discussion, and created a record of the consultation in real time
Number of subjects: 24
Study 10715292 — intervention group
Group type: COMPARATOR
Intervention: Control - researcher observed the consultation
Number of subjects: 24
Study 8649228 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation in infant formula
Number of subjects: 0
Study 8649228 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0
Study 8649228 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 0
Study 1606995 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg alone
Number of subjects: 48
Study 1606995 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg combined with alcohol 0.5 g/kg
Number of subjects: 48
Study 1606995 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule and alcohol 0.5 g/kg
Number of subjects: 48
Study 1606995 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule and placebo drink
Number of subjects: 48
Study 4020207 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg tablet once every fortnight)
Number of subjects: 20
Study 4020207 — intervention group
Group type: COMPARATOR
Intervention: Specific antileprosy treatment (control group)
Number of subjects: 20
Study 29748192 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Regulation (ER) skills training
Number of subjects: 0
Study 29748192 — intervention group
Group type: COMPARATOR
Intervention: Time- and attention-matched comparison group
Number of subjects: 0
Study 27733388 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM ketorolac (nonselective COX inhibitor)
Number of subjects: 23
Study 27733388 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM NG‐nitro‐l‐arginine methyl ester (nonselective NOS inhibitor)
Number of subjects: 23
Study 27733388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both inhibitors (COX and NOS)
Number of subjects: 23
Study 27733388 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control site (lactated Ringer)
Number of subjects: 23
Study 25037746 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement from microalbuminuria to normoalbuminuria after 2 years
Number of subjects: 22984
Study 25037746 — intervention group
Group type: COMPARATOR
Intervention: Deterioration from normoalbuminuria to microalbuminuria
Number of subjects: 22984
Study 25037746 — intervention group
Group type: COMPARATOR
Intervention: Changes in systolic BP control
Number of subjects: 22984
Study 25037746 — intervention group
Group type: COMPARATOR
Intervention: Glucose status
Number of subjects: 22984
Study 22632585 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment
Number of subjects: 115
Study 22632585 — intervention group
Group type: COMPARATOR
Intervention: Self-management
Number of subjects: 115
Study 20662629 — intervention group
Group type: EXPERIMENTAL
Intervention: Body empowerment intervention (manualized, four-session, peer-led, interactive group intervention)
Number of subjects: 189
Study 20662629 — intervention group
Group type: COMPARATOR
Intervention: Control group received HIV Counseling and Testing (HIV-CT) enriched by female condom counseling
Number of subjects: 189
Study 18394446 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed micronized 17beta‐estradiol 1 mg/day
Number of subjects: 180
Study 18394446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 15853097 — intervention group
Group type: EXPERIMENTAL
Intervention: Diafix‐oral (Mueller‐Dental)
Number of subjects: 80
Study 15853097 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS gel (Premier)
Number of subjects: 80
Study 15853097 — intervention group
Group type: EXPERIMENTAL
Intervention: P 403‐W (Dentsply)
Number of subjects: 80
Study 15853097 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlubrush (KerrHawe)
Number of subjects: 80
Study 12426500 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite restorations
Number of subjects: 117
Study 12426500 — intervention group
Group type: COMPARATOR
Intervention: Full-coverage metal-ceramic crowns
Number of subjects: 117
Study 10578189 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic Radiography (PR)
Number of subjects: 37
Study 10578189 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic Radiography combined with Intraoral Radiography (PR+IR)
Number of subjects: 37
Study 10578189 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 37
Study 8952648 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1748814 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% MPD
Number of subjects: 25
Study 1748814 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% MPD
Number of subjects: 25
Study 1748814 — intervention group
Group type: COMPARATOR
Intervention: Skin type
Number of subjects: 25
Study 6291138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 120
Study 6291138 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 120
Study 6291138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 120
Study 6291138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31101617 — intervention group
Group type: EXPERIMENTAL
Intervention: High viral load of species group alpha-9 non-HPV16 oncogenic types
Number of subjects: 439
Study 31101617 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of viral load from low to high levels
Number of subjects: 439
Study 31101617 — intervention group
Group type: EXPERIMENTAL
Intervention: High DNA load of species group alpha-9 non-HPV16 oncogenic types
Number of subjects: 439
Study 28679502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg every 4 hours)
Number of subjects: 89
Study 28679502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 28679502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 89
Study 28679502 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower finishers
Number of subjects: 89
Study 28679502 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater weight loss
Number of subjects: 89
Study 26691817 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (n = 47)
Number of subjects: 95
Study 26691817 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 48)
Number of subjects: 95
Study 22459616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg LGD-4033
Number of subjects: 76
Study 22459616 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg LGD-4033
Number of subjects: 76
Study 22459616 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg LGD-4033
Number of subjects: 76
Study 22459616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 20842429 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 12 months
Number of subjects: 20
Study 20842429 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CT)
Number of subjects: 20
Study 19703065 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming intervention for 6 weeks
Number of subjects: 30
Study 17707751 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg before the intervention, and 200 mg twice daily for 6 months after the procedure)
Number of subjects: 274
Study 17707751 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care with aspirin and clopidogrel)
Number of subjects: 274
Study 17707751 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 274
Study 15204051 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 10
Study 15204051 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 10
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 1 mg
Number of subjects: 206
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 2.5 mg
Number of subjects: 206
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg
Number of subjects: 206
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 206
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 206
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 206
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 80 mg
Number of subjects: 206
Study 11524058 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (all doses)
Number of subjects: 206
Study 11524058 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 206
Study 9284718 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg qd p.o. for four consecutive days starting two days before immunization)
Number of subjects: 71
Study 9284718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 9284718 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 71
Study 8313933 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 30 mg/day
Number of subjects: 24
Study 8313933 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort 60 mg/day
Number of subjects: 24
Study 8313933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3791867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Number of subjects: 10
Study 3791867 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline infusion
Number of subjects: 10
Study 31874290 — intervention group
Group type: EXPERIMENTAL
Intervention: Restarting anticoagulation for stroke prevention in atrial fibrillation after cSDH evacuation
Number of subjects: 81